Hybio Pharmaceutical Gets Domestic Production Approval for Diabetes Drug
Hybio Pharmaceutical (SHE:300199) obtained domestic production approval from China's drug regulator for its liraglutide (H) injection. The drug is indicated for type two diabetes glycemic control, according to a Friday filing with the Shenzhen bourse. Shares of the pharmaceutical company were up 8% in recent trade.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.